CN111065639A - 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 - Google Patents
一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 Download PDFInfo
- Publication number
- CN111065639A CN111065639A CN201980001562.9A CN201980001562A CN111065639A CN 111065639 A CN111065639 A CN 111065639A CN 201980001562 A CN201980001562 A CN 201980001562A CN 111065639 A CN111065639 A CN 111065639A
- Authority
- CN
- China
- Prior art keywords
- compound
- amino
- methyl
- preparation
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
PCT国内申请,说明书已公开。
Claims (13)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018109432511 | 2018-08-17 | ||
CN201810943251.1A CN110835345A (zh) | 2018-08-17 | 2018-08-17 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
PCT/CN2019/100969 WO2020035049A1 (zh) | 2018-08-17 | 2019-08-16 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111065639A true CN111065639A (zh) | 2020-04-24 |
CN111065639B CN111065639B (zh) | 2023-03-10 |
Family
ID=69525215
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810943251.1A Pending CN110835345A (zh) | 2018-08-17 | 2018-08-17 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
CN201980001562.9A Active CN111065639B (zh) | 2018-08-17 | 2019-08-16 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810943251.1A Pending CN110835345A (zh) | 2018-08-17 | 2018-08-17 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN110835345A (zh) |
WO (1) | WO2020035049A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113402520A (zh) * | 2020-03-16 | 2021-09-17 | 中国科学院上海药物研究所 | Wee1蛋白降解剂 |
CN114133394B (zh) * | 2020-08-12 | 2023-12-08 | 赛诺哈勃药业(成都)有限公司 | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 |
CN114349738B (zh) * | 2020-10-14 | 2023-05-05 | 清华大学 | 一类靶向降解cdk2的小分子缀合物及其应用 |
WO2022248682A1 (en) * | 2021-05-28 | 2022-12-01 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) |
CN115521313B (zh) * | 2021-06-24 | 2023-11-03 | 山东大学 | 一种降解btk蛋白的化合物及其制备方法和应用 |
CN116396298A (zh) * | 2023-06-06 | 2023-07-07 | 四川维亚本苑生物科技有限公司 | CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575286A (zh) * | 2001-10-25 | 2005-02-02 | 伊莱利利公司 | 用作抗肿瘤剂的噻吩和噻唑磺酰胺化合物 |
WO2012078492A1 (en) * | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
WO2014063061A1 (en) * | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN107530329A (zh) * | 2015-03-09 | 2018-01-02 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物 |
WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
WO2018119441A1 (en) * | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
-
2018
- 2018-08-17 CN CN201810943251.1A patent/CN110835345A/zh active Pending
-
2019
- 2019-08-16 WO PCT/CN2019/100969 patent/WO2020035049A1/zh active Application Filing
- 2019-08-16 CN CN201980001562.9A patent/CN111065639B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575286A (zh) * | 2001-10-25 | 2005-02-02 | 伊莱利利公司 | 用作抗肿瘤剂的噻吩和噻唑磺酰胺化合物 |
WO2012078492A1 (en) * | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
WO2014063061A1 (en) * | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2015154022A1 (en) * | 2014-04-05 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN107530329A (zh) * | 2015-03-09 | 2018-01-02 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物 |
WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
WO2018119441A1 (en) * | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
Non-Patent Citations (1)
Title |
---|
MAUREEN CALIGIURI,等: "MASPIT: Three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells", 《CHEMISTRY & BIOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111065639B (zh) | 2023-03-10 |
CN110835345A (zh) | 2020-02-25 |
WO2020035049A1 (zh) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111065639B (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
KR102548191B1 (ko) | 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용 | |
EP3381896B1 (en) | Biphenyl compound or salt thereof | |
EP2964222B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
IL262345A (en) | Inhibitors of the kinase-like activin receptor | |
EP2556070B1 (en) | Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones | |
EP3684776B1 (en) | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the cdk12 kinase | |
CN114040914A (zh) | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 | |
CN113286794A (zh) | Kras突变蛋白抑制剂 | |
CN109496213B (zh) | 螺环化合物及其制备和使用方法 | |
EP4212522A1 (en) | Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof | |
HUE032470T2 (en) | Morphinan derivative | |
CN107531714A (zh) | 作为pde1抑制剂的咪唑并吡嗪酮 | |
BR112021011147A2 (pt) | Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
US20110059982A1 (en) | Azaindole compounds for treatment of central nervous system disorders | |
CN115413279A (zh) | P2x3调节剂 | |
CN116323625A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
JP7338896B2 (ja) | Mdm2阻害剤、その調製方法、医薬組成物および応用 | |
JP2023516102A (ja) | ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
IE902786A1 (en) | 1-(Pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments | |
CN114805361B (zh) | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 | |
EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
KR20240019071A (ko) | N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법 | |
WO1999003833A1 (en) | Piperazine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |